- Home
- UBX vs AKTX Comparison
UBX vs AKTX Comparison
Compare UBX & AKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UBX
- AKTX
- Stock Information
- Founded
- UBX 2009
- AKTX N/A
- Country
- UBX United States
- AKTX United States
- Employees
- UBX N/A
- AKTX N/A
- Industry
- UBX Biotechnology: Pharmaceutical Preparations
- AKTX Biotechnology: Pharmaceutical Preparations
- Sector
- UBX Health Care
- AKTX Health Care
- Exchange
- UBX Nasdaq
- AKTX Nasdaq
- Market Cap
- UBX 24.6M
- AKTX 29.5M
- IPO Year
- UBX 2018
- AKTX N/A
- Fundamental
- Price
- UBX $1.00
- AKTX $0.99
- Analyst Decision
- UBX Strong Buy
- AKTX
- Analyst Count
- UBX 1
- AKTX 0
- Target Price
- UBX $8.00
- AKTX N/A
- AVG Volume (30 Days)
- UBX 82.0K
- AKTX 80.4K
- Earning Date
- UBX 11-04-2024
- AKTX 02-15-2025
- Dividend Yield
- UBX N/A
- AKTX N/A
- EPS Growth
- UBX N/A
- AKTX N/A
- EPS
- UBX N/A
- AKTX N/A
- Revenue
- UBX N/A
- AKTX N/A
- Revenue This Year
- UBX N/A
- AKTX N/A
- Revenue Next Year
- UBX $33.62
- AKTX N/A
- P/E Ratio
- UBX N/A
- AKTX N/A
- Revenue Growth
- UBX N/A
- AKTX N/A
- 52 Week Low
- UBX $1.00
- AKTX $0.90
- 52 Week High
- UBX $2.02
- AKTX $4.40
- Technical
- Relative Strength Index (RSI)
- UBX 28.85
- AKTX 31.38
- Support Level
- UBX $1.10
- AKTX $0.95
- Resistance Level
- UBX $1.23
- AKTX $1.13
- Average True Range (ATR)
- UBX 0.06
- AKTX 0.15
- MACD
- UBX -0.01
- AKTX 0.02
- Stochastic Oscillator
- UBX 0.00
- AKTX 15.15
About UBX Unity Biotechnology Inc.
Unity Biotechnology Inc designs therapeutics that prevent, halt, and reverse various diseases of aging. The company focuses on clearing senescent cells, and creating senolytic medicines. Its medicines target vulnerabilities unique to senescent cells to clear those cells from the human body while leaving normal cells unaffected. The firm focuses on age-associated diseases such as osteoarthritis, eye diseases, and pulmonary diseases. Its drug candidates include, UBX1325 is being developed for age-related diseases of the eye, including diabetic macular edema, or DME, UBX2089, which is a circulating hormone primarily produced in the kidneys and choroid plexus of the brain, which is being researched for multiple neurology indications, and UBX2050.
About AKTX Akari Therapeutics plc ADS
Akari Therapeutics PLC is a clinical stage biopharmaceutical company. It is focused on developing therapies for autoimmune and inflammatory diseases involving the complement component 5 (C5) and leukotriene B4 (LTB4) pathways. The company's pipelines include HSCT-TMA and Geographic Atrophy (GA).